These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35304348)

  • 21. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
    Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tubarial salivary gland sparing with proton therapy.
    Wright CM; Lee DY; Kim M; Barsky AR; Teo BK; Lukens JN; Swisher-McClure S; Lin A
    Med Dosim; 2022 Autumn; 47(3):222-226. PubMed ID: 35428548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigations on parotid gland recovery after IMRT in head and neck tumor patients.
    Stock M; Dörr W; Stromberger C; Mock U; Koizar S; Pötter R; Georg D
    Strahlenther Onkol; 2010 Dec; 186(12):665-71. PubMed ID: 21136030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience.
    Claus F; Duthoy W; Boterberg T; De Gersem W; Huys J; Vermeersch H; De Neve W
    Oral Oncol; 2002 Sep; 38(6):597-604. PubMed ID: 12167438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of contralateral submandibular gland sparing in locally advanced oropharyngeal cancers: A multicenter review.
    Robin TP; Gan GN; Tam M; Westerly D; Riaz N; Karam SD; Lee N; Raben D
    Head Neck; 2016 Apr; 38(4):506-11. PubMed ID: 25482748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.
    Lambrecht M; Nevens D; Nuyts S
    Strahlenther Onkol; 2013 Mar; 189(3):223-9. PubMed ID: 23319256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.
    Stokkevåg CH; Indelicato DJ; Herfarth K; Magelssen H; Evensen ME; Ugland M; Nordberg T; Nystad TA; Hægeland C; Alsaker MD; Ulven K; Dale JE; Engeseth GM; Boer CG; Toussaint L; Kornerup JS; Pettersen HES; Brydøy M; Brandal P; Muren LP
    Acta Oncol; 2019 Oct; 58(10):1416-1422. PubMed ID: 31364899
    [No Abstract]   [Full Text] [Related]  

  • 31. NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy.
    Jakobi A; Stützer K; Bandurska-Luque A; Löck S; Haase R; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
    Acta Oncol; 2015; 54(9):1658-64. PubMed ID: 26340301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.
    Schoenfeld JD; Sher DJ; Norris CM; Haddad RI; Posner MR; Balboni TA; Tishler RB
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):308-14. PubMed ID: 21075557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosimetric Evaluation of Incorporating Patient Geometric Variations Into Adaptive Plan Optimization Through Probabilistic Treatment Planning in Head and Neck Cancers.
    Liu Q; Liang J; Zhou D; Krauss DJ; Chen PY; Yan D
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):985-997. PubMed ID: 29976511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
    Bertholet J; Mackeprang PH; Loebner HA; Mueller S; Guyer G; Frei D; Volken W; Elicin O; Aebersold DM; Fix MK; Manser P
    Radiother Oncol; 2024 Jun; 195():110237. PubMed ID: 38513960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obtaining normal tissue constraints using intensity modulated radiotherapy (IMRT) in patients with oral cavity, oropharyngeal, and laryngeal carcinoma.
    Skinner WK; Muse ED; Yaparpalvi R; Guha C; Garg MK; Kalnicki S
    Med Dosim; 2009; 34(4):279-84. PubMed ID: 19854386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beam intensity modulation using tissue compensators or dynamic multileaf collimation in three-dimensional conformal radiotherapy of primary cancers of the oropharynx and larynx, including the elective neck.
    van Dieren EB; Nowak PJ; Wijers OB; van Sörnsen de Koste JR; van der Est H; Binnekamp DP; Heijmen BJ; Levendag PC
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1299-309. PubMed ID: 10889384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volumetric modulated arc therapy (VMAT) and simultaneous integrated boost in head-and-neck cancer: is there a place for critical swallowing structures dose sparing?
    Cilla S; Deodato F; Macchia G; Digesù C; Ianiro A; Piermattei A; Valentini V; Morganti AG
    Br J Radiol; 2016; 89(1059):20150764. PubMed ID: 26728543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy.
    Taku N; Wang L; Garden AS; Rosenthal DI; Gunn GB; Morrison WH; Fuller CD; Phan J; Reddy JP; Moreno AC; Spiotto MT; Chronowski G; Shah SJ; Mayo LL; Gross ND; Ferrarotto R; Zhu XR; Zhang X; Frank SJ
    Curr Treat Options Oncol; 2021 Jun; 22(6):54. PubMed ID: 34086150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.